Validation of a method for the determination of Aderamastat (FP-025) in K2EDTA human plasma by LC-MS/MS
-
Published:2024-09
Issue:
Volume:1245
Page:124244
-
ISSN:1570-0232
-
Container-title:Journal of Chromatography B
-
language:en
-
Short-container-title:Journal of Chromatography B
Author:
Abd-Elaziz Khalid S.ORCID,
Cheng Rex,
Chen Joe,
Maarse Hans,
Lee Yisheng,
Yang Wenjin,
Chien Benjamin,
Diamant Zuzana,
Kosterink Jos,
Touw Daniël J.
Reference24 articles.
1. Revisiting matrix metalloproteinase 12: its role in pathophysiology of asthma and related pulmonary diseases;Abd-Elaziz;Curr. Opin. Pulm. Med.,2021
2. K. Abd-Elaziz,C. Voors-Pette,K-L. Wang,S. Pan,Y. Lee,J. Mao,Y. Li,B. Chien,D. Lau,Z. Diamant. First-in-Man Safety, Tolerability, and Pharmacokinetics of a Novel and Highly Selective Inhibitor of Matrix Metalloproteinase-12, FP-025: Results from Two Randomized Studies in Healthy Subjects. Clin Drug Investig;.2021 Jan;41(1):65-76. doi: 10.1007/s40261-020-00981-9.
3. Biological role of matrix metalloproteinases: a critical balance;Loffek;Eur. Respir. J.,2011
4. Structure and function of matrix metalloproteinases and TIMPs;Nagase;Cardiovasc. Res.,2006
5. Is there new hope for therapeutic matrix metalloproteinase inhibition?;Vandenbroucke;Nat. Rev. Drug Discov.,2014